Aspen Pharmacare Holdings Limited
http://www.aspenpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aspen Pharmacare Holdings Limited
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Aspen Explains U-Turn On Withdrawing From Proposed API Sale
Following years of reshaping its operations, one part of Aspen Pharmacare’s business that is to stay for now is the firm’s API division. The South African firm’s management explained why as Aspen presented results from its financial first half, hours after wrapping up a key COVID-19 licensing deal with Johnson & Johnson.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Other Names / Subsidiaries
-
- Aspen Global Incorporated (AGI)
- Aspen Japan K.K.